29-06-2018
The new website aims to further strengthen Inke’s prestige in the industry as a developer and manufacturer of high-quality active ingredients (APIs), mainly for respiratory inhalation and central nervous system (CNS) uses.
Inke’s new corporate identity, which also ties in with the Group’s identity through images of the sea and wind, is represented by plants on the seashore moving in the breeze and symbolises the products indicated for the treatment of diseases that limit patients’ breathing, while also transmitting a feeling of calm to patients suffering from CNS disorders.
During 2023, Inke has increased its production capacity by making a significant investment in new reactors and clean rooms. This initiative has been carried out with the support of ACCIÓ from the Generalitat de Catalunya.
Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity.
